Morgan Stanley raised the firm’s price target on Johnson & Johnson to $283 from $267 and keeps an Overweight rating on the shares. The firm tweaks 2026 and beyond estimates higher after J&J posted a Q1 beat and slightly raised 2026 guidance, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $265 from $255 at RBC Capital
- Protagonist Therapeutics price target raised to $121 from $110 at Truist
- Johnson & Johnson price target raised to $250 from $220 at Stifel
- Johnson & Johnson price target raised to $255 from $234 at Barclays
- Johnson & Johnson Bets Big on Next-Gen Growth